Further improvement after 24-month treatment with teduglutide in a patient with active Crohn's disease and short bowel syndrome.

Abstract

Treatment with the glucagon-like peptide 2 (GLP-2) analog teduglutide is generally associated with clinically significant reductions (≥20% from baseline) in the parenteral nutrition (PN) volume in adult patients with short bowel syndrome (SBS) (1,2). Teduglutide has demonstrated to be safe and well tolerated, leading to restoration of intestinal functional and structural integrity. On the other hand, adverse events related to hyperplastic and hypertrophic effects have also been reported (3). Thus, patients with SBS and with fluctuations in disease activity, for example, in active Crohn’s disease (CD), have never been treated with teduglutide.